Prospects of siponimod in secondary progressive multiple sclerosis

被引：2
|
作者：
McGinley, Marisa [1 ]
Fox, Robert J. [1 ]
机构：
[1] Cleveland Clin, 9500 Euclid Ave,U-10, Cleveland, OH 44120 USA
来源：
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS | 2018年 / 11卷
关键词：
D O I：
10.1177/1756286418788013
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study
    Fox, R.
    Arnold, D. L.
    Bar-Or, A.
    Cree, B.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Pohlmann, H.
    Sidorenko, T.
    Wolf, C.
    Tomic, D.
    Dahlke, F.
    Kappos, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 34 - 35
  • [42] ECONOMIC SAVINGS FROM DELAYING TIME TO WHEELCHAIR WITH SIPONIMOD IN ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS IN PORTUGAL
    Bandeiras, C.
    Silva, C.
    Esparteiro, J.
    Fernandes, P.
    Costa, A.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S625 - S625
  • [43] Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
    Skoric, Magdalena Krbot
    Rogic, Dunja
    Lapic, Ivana
    Segulja, Dragana
    Habek, Mario
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [44] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Lam, E.
    Pohlmann, H.
    Zhang-Auberson, L.
    Dandekar, A.
    Wallstrom, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 927 - 928
  • [45] Basic immunological profile changes with BAF312 (siponimod) treatment in secondary progressive multiple sclerosis patients
    Mao-Draayer, Y.
    Wu, Q.
    Wang, Q.
    Dowling, C.
    Lundy, S.
    Fox, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 1015 - 1015
  • [46] Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
    Sabsabi, Sajida
    Mikhael, Elio
    Jalkh, Georges
    Macaron, Gabrielle
    Rensel, Mary
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 1307 - 1319
  • [47] Baseline characteristics of amasia: first real world data of siponimod treated patients with secondary progressive multiple sclerosis
    Weber, M.
    Klotz, L.
    Schreiber, H.
    Rauser, B.
    Ziemssen, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 518 - 518
  • [48] The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
    Valis, Martin
    Achiron, Anat
    Hartung, Hans Peter
    Mares, Jan
    Ticha, Veronika
    Stourac, Pavel
    Haluskova, Simona
    Angelucci, Francesco
    Pavelek, Zbysek
    [J]. DRUGS IN R&D, 2023, 23 (04) : 331 - 338
  • [49] Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis
    Gilmartin, Christopher G. S.
    Hoyle, Natasha
    Garjani, Afagh
    Dixon, Terri
    Jos, Helena
    Paling, David
    Brownlee, Wallace
    Tench, Christopher
    Evangelou, Nikos
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (4-5) : 600 - 604
  • [50] Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis
    Habek, Mario
    Crnosija, Luka
    Junakovic, Anamari
    Adamec, Ivan
    Barun, Barbara
    Gabelic, Tereza
    Skoric, Magdalena Krbot
    [J]. CLINICAL NEUROPHYSIOLOGY, 2021, 132 (02) : 581 - 585
12345